Catheter‐related blood stream infection · any patient requiring a PIVC expected to remain in‐situ for at least 3 days
Effects of clinically‐indicated replacement showed no clear difference in catheter‐related blood stream infection (during hospitalisation) compared with routine change of peripheral intravenous catheters (low certainty).
1 finding from 1 review
Thrombophlebitis (during hospitalisation) · any patient requiring a PIVC expected to remain in‐situ for at least 3 days
Effects of clinically‐indicated replacement showed no clear difference in thrombophlebitis (during hospitalisation) compared with routine change of peripheral intravenous catheters (moderate certainty).
1 finding from 1 review
Thrombophlebitis (per device days) (during hospitalisation) · any patient requiring a PIVC expected to remain in‐situ for at least 3 days
Effects of clinically‐indicated replacement showed no clear difference in thrombophlebitis (per device days) (during hospitalisation) compared with routine change of peripheral intravenous catheters (moderate certainty).
1 finding from 1 review
All‐cause blood stream infection (during hospitalisation) · any patient requiring a PIVC expected to remain in‐situ for at least 3 days
Effects of clinically‐indicated replacement showed no clear difference in all‐cause blood stream infection (during hospitalisation) compared with routine change of peripheral intravenous catheters (moderate certainty).
1 finding from 1 review
Cost of hospitalisation · any patient requiring a PIVC expected to remain in‐situ for at least 3 days
1 finding from 1 review
Infiltration (during hospitalisation) · any patient requiring a PIVC expected to remain in‐situ for at least 3 days
Effects of clinically‐indicated replacement probably leads to higher infiltration (during hospitalisation) compared with routine change of peripheral intravenous catheters (moderate certainty).
1 finding from 1 review
Catheter blockage (during hospitalisation) · any patient requiring a PIVC expected to remain in‐situ for at least 3 days
Effects of clinically‐indicated replacement probably leads to higher catheter blockage (during hospitalisation) compared with routine change of peripheral intravenous catheters (moderate certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC probably leads to lower symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC leads to lower symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding‐ clinically relevant non‐major Treatment duration 28 ‐ 42… compared with placebo (moderate certainty).
1 finding from 1 review
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review